Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

May 11, 2015
Several clinical trials have shown that for women with ovarian cancer, IP chemotherapy–which allows the drugs to be delivered directly into the peritoneum at a 20- to 1000-fold greater concentration than IV chemotherapy—confers survival advantages.
May 04, 2015
During the past two decades, there has been an increase in the number of long-term survivors of autologous and allogeneic hematopoietic stem-cell transplantations (HSCT).
Apr 27, 2015
For women with metastatic or recurrent cervical cancer, paclitaxel plus carboplatin confers the same survival advantage as paclitaxel plus cisplatin, currently the standard of care (overall survival [OS] was 17.5 months in the carboplatin group versus 18.3 months in the cisplatin group)...
Apr 13, 2015
The study found that among the 35% of patients who expressed a strong desire for genetic testing, 196 (43.4%) did not have a relevant discussion...
Apr 06, 2015
A study in the Journal of Clinical Oncology (JCO) set out to answer two questions: What are the rates of adherence to these new distress-screening and referral requirements at two tertiary cancer care centers and, do clinicians find the screening useful?
Mar 23, 2015
“Physicians who are part of a larger, more integrated care delivery system might be better able to plan a response to a drug shortage. Another possibility is that larger organizations have more purchasing power or ability to engage in the market.”
Mar 16, 2015
Among patients with prostate cancer being treated with continuous (non-intermittent) androgen deprivation therapy, those whose testosterone dipped to a nadir of less than 20 nanograms per deciliter within the first year of treatment experienced improved survival and . . .
Mar 09, 2015
For children and adolescents being treated for acute lymphoblastic leukemia, those who receive a stem-cell transplant from an unrelated donor have the same overall survival as those who receive the transplant from a sibling. 
Mar 02, 2015
"The study found that over a 14-week period, incidence of HFSR—of any grade—was lower among patients who started using the urea-based cream at the start of treatment, compared to patients who received best supportive care alone." 
Feb 23, 2015
According to first author, Dirk Schadendorf, MD, the study is “The first meta-analysis looking at Ipilimumab. It is also the largest analysis of melanoma patients ever conducted, with close to 5000 patients  . . ."

Pages